As I have said before there are so many ways to value a company,the only good one I know of can not be applied to ONCS because it has no revenue. So we have to make several assumptions about how successful they will be, how many indications they will have, when they will be approved, and what things will sell for. That is at least 4 variables with no real range to use for estimations. I think for now the safest way to do it would be to go off of IL-12 giving a 150%-200% boost in sales to Keytruda (slated to generate $1.5B in 2017) So if the combination is approved by early 2017, ImmunoPulse could generate $2-$3B in additional revenue per year for Keytruda and other PD1 drugs. What is that valued at? My conservative estimation would be a market Cape of $2B (assuming ONCS goes no further than Melanoma combination) and if a buyout happens, I'd say it will be at a multiple of 5-6x, $10-$12B.
News 
Market Data 
Discover 
